Dupixent Lawsuits: Information for Cutaneous T-Cell Lymphoma Cancer Patients

Attorneys working with ClassAction.org are now looking to file lawsuits on behalf of patients who used Dupixent and were diagnosed with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin lymphoma primarily affecting the skin.

Allegations have surfaced that the injectable medication (also available as the generic dupilumab) can cause cutaneous T-cell lymphoma to develop or, alternatively, aggravate a pre-existing CTCL in the patient.

According to recently filed Dupixent lawsuits, the manufacturers knew or should have known about the potential link between Dupixent and cutaneous T-cell lymphoma from medical studies (including their own), presentations at professional conferences and FDA adverse event reports, yet failed to warn patients and doctors about this risk.

Indeed, there is currently no warning on the U.S. label for Dupixent about cutaneous T-cell lymphoma—and the FDA is currently evaluating the need for regulatory action over the potential risk.

Who Can File a Dupixent Lawsuit?

Patients who used Dupixent, an injectable drug used to treat eczema (atopic dermatitis), asthma, COPD and more, and were diagnosed with certain forms of T-cell lymphoma may be able to file a lawsuit against the drug’s manufacturers.

Attorneys are specifically investigating cases in which Dupixent may have caused a new cutaneous T-cell lymphoma to develop, as well as those in which a pre-existing CTCL was “unmasked” or made worse by the drug. In the latter cases, it’s possible that the cutaneous T-cell lymphoma was initially misdiagnosed as atopic dermatitis, or eczema.

What Is T-Cell Lymphoma?

Generally speaking, lymphoma refers to a type of cancer affecting the lymphatic system, a group of organs, vessels and tissues that help fight infection and disease.

T-cell lymphoma specifically refers to a type of cancer that forms in the T lymphocytes, a type of white blood cell also referred to as a “T cell.” A form of non-Hodgkin lymphoma, T-cell lymphomas can affect the lymph nodes, bone marrow, blood and other tissues throughout the body, such as in the gastrointestinal tract, liver and skin, according to the Mayo Clinic. Several different types of T-cell lymphomas exist.

Two subtypes of cutaneous T-cell lymphoma are mycosis fungoides and the less common Sézary syndrome. According to the American Academy of Dermatology Association, mycosis fungoides often first presents as a rash or “sunburn” on the upper thigh, butt, groin or stomach that can “last for months or years.” Sézary syndrome, in which cancerous T cells are present in the blood, skin and lymph nodes, can cause tumors on the skin, peeling skin, nail changes and an “all over” rash; this form of cutaneous T-cell lymphoma can also cause the skin to feel hot, sore and extremely itchy. In some cases, mycosis fungoides can eventually turn into Sézary syndrome.

Is This a Dupixent Class Action Lawsuit?

No, attorneys working with ClassAction.org are not handling Dupixent lawsuits as a class action. This is because they believe the harm suffered by patients and their families is severe enough to warrant individual Dupixent lawsuits. Typically, a class action lawsuit seeks compensation for a relatively small loss, such as the amount of added fees on tickets to a sporting event, suffered by a large number of individuals.

You can learn more about the difference between class actions and individual injury lawsuits.

What Compensation Can You Expect from a Dupixent Lawsuit for Cancer?

In a Dupixent death lawsuit where the individual passed away due to their cancer diagnosis, compensation for funeral expenses could also be recovered.

What’s Involved in Filing a Dupixent Lawsuit for Lymphoma?

If you qualify for a Dupixent cancer lawsuit, your attorney will begin by gathering relevant information and documentation (e.g., medical records) to compile your case. He or she may ask when the individual began using Dupixent, what the medication was prescribed for, when the diagnosis of cutaneous T-cell lymphoma was made and what treatment was received. Your Dupixent cancer attorney will also attempt to understand how the diagnosis impacted the patient and their family.

Once this information has been gathered, your Dupixent attorney will begin to put together a “complaint,” the legal document that outlines the allegations you are making against the drug’s manufacturers, why the companies should be responsible for your losses and the damages you are seeking.

When the complaint is filed with the court, your lawsuit officially begins.

After filing, your Dupixent attorneys and the defendants’ attorneys will work back and forth to try to resolve the case—whether that results in a dismissal, settlement, or, less commonly, jury trial.

Throughout the process, you will remain in contact with your attorney who can provide you with updates on your Dupixent lawsuit.

How Much Does It Cost to File a Lawsuit Against Dupixent?

Attorneys working with ClassAction.org are handling Dupixent lawsuits for cancer on a contingency-fee basis. This means that they will only get paid if they win your case, and their payment will come as a percentage of any Dupixent settlement or jury award you receive.

Do Dupixent Side Effects Include Lymphoma?

Scientific research has suggested a possible link between use of Dupixent (dupilumab) and the development or exacerbation of cutaneous T-cell lymphoma, with allegations surfacing that this information should have alerted the drug’s manufacturers to the risk, which is still not included on Dupixent’s labeling. 

For instance, a retrospective cohort study first published in April 2024 found that dupilumab (Dupixent) use is associated with an increased risk of cutaneous T-cell lymphoma in eczema patients. The study used a large database to compare the incidence of the lymphoma, along with other malignancies, in atopic dermatitis patients who used dupilumab compared to those who never used the medication.

Additionally, a research article published in the Dermatologic Therapy journal in August 2024 using the same database found that use of Dupixent for eczema was associated with an “increased relative risk” of developing cutaneous T-cell lymphoma. Notably, the article cautioned that physicians should thoroughly evaluate adult patients without a prior history of atopic conditions before prescribing Dupixent, specifically in cases where eczema develops later in life, progresses rapidly or is otherwise atypical. It also advised that patients whose skin conditions are resistant to dupilumab receive skin biopsies to help ensure the correct diagnosis given that eczema and cutaneous T-cell lymphoma can share similar symptoms. At least one Dupixent lawsuit alleges doctors who have prescribed Dupixent to patients who were later diagnosed with cutaneous T-cell lymphoma have presented their concerns at medical conferences, which are believed to have been attended by employees of Regeneron and Sanofi, and to sales representatives directly.

In another example, a research letter published in a July 2020 issue of the Journal of the American Academy of Dermatology detailed a chart review of seven patients, four of whom received dupilumab for clinically presumed eczema and three of whom had the medicine prescribed off label for cutaneous T-cell lymphoma. The four patients with supposed eczema were eventually diagnosed with cutaneous T-cell lymphoma, while the other three original lymphoma patients experienced progression of their cancer, with two eventually dying from the disease, the article said. 

Additionally, a case report published in a February 2021 American Academy of Dermatology journal detailed the experience of a healthy 43-year-old man who, since childhood, had “mild but persistent” bouts of atopic dermatitis. Over a 12-month period, however, the man noticed worsening symptoms, including increased dryness and flakiness, along with painful fissures on the hands and feet that were “uncharacteristic of his typical disease.” Physicians ordered dupilumab injections (previous treatments had included corticosteroids) and, two months later, the man returned with worsening of his dermatitis, weight loss of 10 to 15 pounds and significantly swollen lymph nodes. Testing was performed, and the man was diagnosed with a form of cutaneous T-cell lymphoma known as mycosis fungoides.

Another study analyzing the potential Dupixent T-cell lymphoma risk among asthma patients found that recipients of dupilumab had a higher risk of lymphoma, specifically T-cell and NK-cell lymphomas, and argued for more research on the possible connection. 

Additional research about a possible link between Dupixent and cutaneous T-cell lymphoma includes a case study published in Dermatology in August 2020, a review article published in Dermatitis and a brief report published in an April 2025 issue of the Journal of the American Academy of Dermatology.

A small number of patients have taken to the eczema subreddit to express concerns about studies linking Dupixent to cutaneous T-cell lymphoma, with one user commenting that the research is “pretty frightening” and that they want to fix their eczema but “not to get cancer.” A fellow user stated that the potential Dupixent lymphoma risk makes them feel “a bit apprehensive,” with another adding that their 47-year-old husband used Dupixent and, after three injections, found his white blood cells were altered, eventually leading to a cutaneous T-cell lymphoma diagnosis.

The FDA is currently evaluating the need for regulatory action based on reports submitted to its Adverse Event Reporting System signaling a potential link between Dupixent and cutaneous T-cell lymphoma. 

How Could Dupixent Potentially Cause Cancer?

Dupixent (dupilumab) is a biologic medication, a type of specialty medicine that’s made from living organisms and can be designed to target certain parts of the immune system associated with a specific disease. Unfortunately, attorneys suspect that Dupixent may cause cutaneous T-cell lymphoma to develop or potentially aggravate a pre-existing CTCL via the same mechanism it uses to help treat eczema.

Specifically, Dupixent works by blocking signals from two immune messengers that drive skin inflammation, and concerns have been raised that this change in immune signaling could “unmask” or accelerate an underlying T-cell lymphoma.

Does Dupixent Have a Black Box Warning?

There is currently no black box warning on Dupixent; however, the labeling notes that the most common Dupixent side effects may include joint pain, injection site reactions, cold sores, insomnia, toothache, upper respiratory tract infections, eye and eyelid inflammation, throat pain, toothache and gastritis.

Before commenting, please review our comment policy.